Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PharmaCyte Biotech, Inc.PMCB · Entity 8256 | Director | August 15, 2022 | August 24, 2022 |
| Profusa, Inc.PFSA · Entity 2740 | Chief Executive Officer | August 21, 2026 | September 04, 2026 |
| Transcode Therapeutics, Inc.RNAZ · Entity 8499 | Director | December 19, 2025 | December 22, 2025 |
| Traws Pharma, Inc.TRAW · Entity 8032 | Director | July 09, 2026 | July 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PharmaCyte Biotech, Inc.
Report date August 15, 2022 · Filed August 24, 2022
This filing explicitly reported no securities owned.
Profusa, Inc.
Report date August 21, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,091 |
Reported balance
After 2026-08-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-21 · Other · Acquired 32,018 · Balance 32,091 F1: Pro rata distribution from NorthView Sponsor I LLC, of which the reporting person is a manager. F2: Includes 73 shares held directly by the reporting person. |
| Common StockSEC Table I · non-derivative | IndirectBy NorthView Sponsor I LLC | 0 |
Reported balance
After 2026-08-21 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-08-21 · Other · Disposed 301,991 · Balance 0 F3: On August 21, 2026, NorthView Sponsor I LLC distributed all its shares of Issuer's common stock to its members, including 32,018 shares to the reporting person. F4: Jack Stover is a manager of NorthView Sponsor I LLC and may be deemed to share beneficial ownership of the securities held by NorthView Sponsor I LLC. Mr. Stover disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Pro rata distribution from NorthView Sponsor I LLC, of which the reporting person is a manager.
F2: Includes 73 shares held directly by the reporting person.
F3: On August 21, 2026, NorthView Sponsor I LLC distributed all its shares of Issuer's common stock to its members, including 32,018 shares to the reporting person.
F4: Jack Stover is a manager of NorthView Sponsor I LLC and may be deemed to share beneficial ownership of the securities held by NorthView Sponsor I LLC. Mr. Stover disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Transcode Therapeutics, Inc.
Report date December 19, 2025 · Filed December 22, 2025
This filing explicitly reported no securities owned.
Traws Pharma, Inc.
Report date July 09, 2026 · Filed July 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2036-07-09 | Direct | 14,150 |
Reported balance
After 2026-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-09 · Grant · Acquired 14,150 · Balance 14,150 F1: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
INTERPACE BIOSCIENCES, INC.
Report date December 01, 2020 · Filed December 02, 2020
Section 16 reporting ended · disclosed 2020-12-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2030-11-30 | Direct | 43,750 |
Reported balance
After 2020-12-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-01 · Grant · Acquired 43,750 · Balance 43,750 F1: The options vest immediately. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest immediately.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 21, 2026 Filed Sep 4, 2026 14:47 UTC | Profusa, Inc. PFSA · Entity 2740 | OtherCommon Stock | 301,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-097490 · ownership.xml · nonDerivative · entry 2 STOVER JACK E · CIK 0001203603 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By NorthView Sponsor I LLC Disclosed balance after: 0 F3 · balance_after: On August 21, 2026, NorthView Sponsor I LLC distributed all its shares of Issuer's common stock to its members, including 32,018 shares to the reporting person. F4 · ownership.nature: Jack Stover is a manager of NorthView Sponsor I LLC and may be deemed to share beneficial ownership of the securities held by NorthView Sponsor I LLC. Mr. Stover disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 21, 2026 Filed Sep 4, 2026 14:47 UTC | Profusa, Inc. PFSA · Entity 2740 | OtherCommon Stock | 32,018 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-097490 · ownership.xml · nonDerivative · entry 1 STOVER JACK E · CIK 0001203603 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,091 F1 · shares: Pro rata distribution from NorthView Sponsor I LLC, of which the reporting person is a manager. F2 · balance_after: Includes 73 shares held directly by the reporting person. Read SEC document |
| August 12, 2026 Filed Aug 20, 2026 00:13 UTC | Profusa, Inc. PFSA · Entity 2740 | ConversionConvertible Promissory Note · Derivative | Not disclosed | $0.00 Strike: $4.28 | $1,292,521.00 |
DisclosureSEC source: 0001213900-26-091839 · ownership.xml · derivative · entry 3 STOVER JACK E · CIK 0001203603 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By NorthView Sponsor I LLC Disclosed balance after: Not disclosed Underlying: Common Stock · 301,991 shares Expires 2026-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The conversion price is equal to the higher of (i) $1.07 and (ii) the closing price of the Common Stock on the trading day immediately preceding the delivery of the Conversion Notice, as reported on The Nasdaq Stock Market, pursuant to Amendment No. 3 to the Note Modification and Conversion Agreement dated August 12, 2026. The pre-split conversion price of $1.07 per share is equivalent to $4.28 per share on a post-split basis following the 1-for-4 reverse stock split. F4 · reported_value: Represents the conversion of $1,292,521 principal amount of the Convertible Promissory Note into 1,207,964 shares of Common Stock (301,991 shares on a post-split basis), reflecting conversion at the $1.07 per share ($4.28 per share on a post-split basis) price pursuant to the Conversion Notice dated August 12, 2026. F5 · derivative.exercise_date: The Note became convertible on May 4, 2026 (the Registration Effective Date), pursuant to Section 2.1 of the Note Modification and Conversion Agreement dated April 24, 2026. F1 · derivative.underlying_shares: On August 12, 2026, 1,207,964 shares of Common Stock were issued upon conversion of a portion of the Convertible Promissory Note. Following a 1-for-4 reverse stock split effected after the conversion, the number of shares held became 301,991. F6 · valueOwnedAfter: Represents the remaining principal balance of the Note following conversion. F3 · ownership.nature: Jack Stover is a manager of NorthView Sponsor I LLC and may be deemed to share beneficial ownership of the securities held by NorthView Sponsor I LLC. Mr. Stover disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 12, 2026 Filed Aug 20, 2026 00:13 UTC | Profusa, Inc. PFSA · Entity 2740 | ConversionCommon Stock | 301,991 | $4.28 | $1,292,521.48 |
DisclosureSEC source: 0001213900-26-091839 · ownership.xml · nonDerivative · entry 1 STOVER JACK E · CIK 0001203603 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By NorthView Sponsor I LLC Disclosed balance after: 301,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On August 12, 2026, 1,207,964 shares of Common Stock were issued upon conversion of a portion of the Convertible Promissory Note. Following a 1-for-4 reverse stock split effected after the conversion, the number of shares held became 301,991. F2 · price: The conversion price is equal to the higher of (i) $1.07 and (ii) the closing price of the Common Stock on the trading day immediately preceding the delivery of the Conversion Notice, as reported on The Nasdaq Stock Market, pursuant to Amendment No. 3 to the Note Modification and Conversion Agreement dated August 12, 2026. The pre-split conversion price of $1.07 per share is equivalent to $4.28 per share on a post-split basis following the 1-for-4 reverse stock split. F1 · balance_after: On August 12, 2026, 1,207,964 shares of Common Stock were issued upon conversion of a portion of the Convertible Promissory Note. Following a 1-for-4 reverse stock split effected after the conversion, the number of shares held became 301,991. F3 · ownership.nature: Jack Stover is a manager of NorthView Sponsor I LLC and may be deemed to share beneficial ownership of the securities held by NorthView Sponsor I LLC. Mr. Stover disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 09, 2026 Filed Jul 15, 2026 01:57 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to buy) · Derivative | 14,150 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001203603-26-000003 · form4-07152026_010731.xml · derivative · entry 1 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,150 Underlying: Common Stock · 14,150 shares Expires 2036-07-09 F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. Read SEC document |
| May 04, 2026 Filed May 6, 2026 14:42 UTC | Profusa, Inc. PFSA · Entity 2740 | PurchaseConvertible Promissory Note · Derivative | Not disclosed | $1,869,796.00 Strike: $0.35 | $1,869,796.00 |
DisclosureSEC source: 0001213900-26-052627 · ownership.xml · derivative · entry 1 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By NorthView Sponsor I LLC Disclosed balance after: Not disclosed Underlying: Common Stock · 5,342,274 shares Expires 2026-12-31 F1 · derivative.exercise_price: The conversion price is equal to the greater of (i) 95% of the closing price of the Common Stock on the Conversion Date and (ii) $0.35 per share, pursuant to the Note Modification and Conversion Agreement dated April 24, 2026. F2 · derivative.exercise_date: The Note became exercisable (convertible) on the Registration Effective Date, pursuant to Section 2.1 of the Note Modification and Conversion Agreement dated April 24, 2026. F3 · derivative.underlying_shares: Represents the conversion of the entire outstanding principal balance of the Second Amended and Restated Promissory Note, dated April 6, 2026, in the amount of $1,869,796 into 5,342,274 shares of Common Stock, reflecting conversion at the $0.35 per share floor price. F4 · ownership.nature: Mr. Knechtel is the managing member of NorthView Sponsor I LLC and may be deemed to share beneficial ownership of the securities held by NorthView Sponsor I LLC. Mr. Knechtel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 08, 2026 Filed Mar 10, 2026 23:16 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to buy) · Derivative | 33,435 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001203603-26-000001 · form4-03102026_110316.xml · derivative · entry 1 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,435 Underlying: Common Stock · 33,435 shares Expires 2036-03-08 F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. Read SEC document |
| January 26, 2026 Filed Jan 29, 2026 18:55 UTC | Profusa, Inc. PFSA · Entity 2740 | GrantStock Options · Derivative | 52,866 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001213900-26-009374 · ownership.xml · derivative · entry 2 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,866 Underlying: Common Stock · 52,866 shares Expires 2036-01-26 F2 · shares: Represents an annual director award of options to purchase common stock. The options vest on the first anniversary of the Closing. Read SEC document |
| January 26, 2026 Filed Jan 29, 2026 18:55 UTC | Profusa, Inc. PFSA · Entity 2740 | GrantStock Options · Derivative | 221,794 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001213900-26-009374 · ownership.xml · derivative · entry 1 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,794 Underlying: Common Stock · 221,794 shares Expires 2036-01-26 F1 · shares: Represents an inaugural director award of options to purchase common stock. The options vest in three equal annual increments over a period of three years from the closing of the business combination between the Issuer (formerly known as NorthView Acquisition Corp.) and Profusa, Inc. (the "Closing"). Read SEC document |
| January 26, 2026 Filed Jan 30, 2026 21:27 UTC | Profusa, Inc. PFSA · Entity 2740 | OtherWarrants · Derivative | 380,280 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001213900-26-010228 · ownership.xml · derivative · entry 2 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,280 Underlying: Common Stock · 380,280 shares Expires 2030-07-11 F1 · kind: Represents the distribution for no consideration by NorthView Sponsor I LLC (the "Sponsor") to the Reporting Person of (i) 553,665 shares of Common Stock, and (ii) 380,280 warrants to purchase shares of Common Stock, in connection with a pro rata distribution of Issuer securities held by the Sponsor to its members. Read SEC document |
| January 26, 2026 Filed Jan 30, 2026 21:27 UTC | Profusa, Inc. PFSA · Entity 2740 | OtherCommon Stock | 553,665 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-010228 · ownership.xml · nonDerivative · entry 1 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 553,665 F1 · kind: Represents the distribution for no consideration by NorthView Sponsor I LLC (the "Sponsor") to the Reporting Person of (i) 553,665 shares of Common Stock, and (ii) 380,280 warrants to purchase shares of Common Stock, in connection with a pro rata distribution of Issuer securities held by the Sponsor to its members. F1 · price: Represents the distribution for no consideration by NorthView Sponsor I LLC (the "Sponsor") to the Reporting Person of (i) 553,665 shares of Common Stock, and (ii) 380,280 warrants to purchase shares of Common Stock, in connection with a pro rata distribution of Issuer securities held by the Sponsor to its members. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 23:20 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 24,629 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001203603-25-000006 · form4-12162025_111205.xml · derivative · entry 2 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,629 Underlying: Common Stock · 24,629 shares Expires 2035-12-12 F2 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 23:20 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantCommon Stock | 6,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001203603-25-000006 · form4-12162025_111205.xml · nonDerivative · entry 1 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,165 F1 · shares: Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis. Read SEC document |
| October 12, 2025 Filed Oct 16, 2025 00:05 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 11,530 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001203603-25-000005 · form4-10162025_121008.xml · derivative · entry 1 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,530 Underlying: Common Stock · 11,530 shares Expires 2035-10-12 F1 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date. Read SEC document |
| June 19, 2025 Filed Jun 23, 2025 21:54 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 23,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001415889-25-017996 · form4-06232025_090657.xml · derivative · entry 1 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2035-06-19 F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:52 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 66,468 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001415889-23-012232 · form4-08142023_090802.xml · derivative · entry 1 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,468 Underlying: Common Stock · 66,468 shares Expires 2033-08-10 F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 21:10 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 66,468 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001415889-22-008914 · form4-08192022_050801.xml · derivative · entry 1 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,468 Underlying: Common Stock · 66,468 shares Expires 2032-08-18 F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date. Read SEC document |
| December 20, 2021 Filed Dec 23, 2021 22:27 UTC | Profusa, Inc. NVAC · Entity 2740 | PurchasePrivate Warrants to purchase common stock · Derivative | 5,162,500 | $1.00 Strike: $11.50 | $5,162,500.00 |
DisclosureSEC source: 0001213900-21-067370 · ownership.xml · derivative · entry 1 STOVER JACK E · CIK 0001203603 · Director · Chief Executive Officer · 10% owner NorthView Sponsor I, LLC · CIK 0001890761 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By NorthView Sponsor I, LLC Disclosed balance after: 5,162,500 Underlying: Common stock · 5,162,500 shares Expires not disclosed F1 · shares: NorthView Sponsor I, LLC ("Sponsor") purchased 5,162,500 warrants on December 20, 2021, as described in the issuer's registration statement on Form S-1 (File No. 333-257156), in a private placement of warrants at a price of $1.00 per private placement warrant. Each whole private placement warrant is exercisable to purchase one share of common stock at a price of $11.50 per share. F2 · derivative.exercise_date: The warrants become exercisable on the later of (i) 30 days after the completion of the registrant's initial business combination and (ii) 12 months from the closing of the registrant's initial public offering. F3 · derivative.expiration_date: The warrants expire five years after the completion of the registrant's initial business combination or earlier upon redemption or liquidation, as described in the Form S-1 (File No. 333-257156). F4 · ownership.nature: The warrants are held by Sponsor. Jack Stover is the manager of the Sponsor. Mr. Stover disclaims beneficial ownership of the securities held by the Sponsor except to the extent of his pecuniary interest therein. Read SEC document |
| July 30, 2021 Filed Jul 30, 2021 23:21 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 13,000 | $0.00 Strike: $4.97 | $0.00 |
DisclosureSEC source: 0001179110-21-007792 · edgar.xml · derivative · entry 1 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2031-07-30 F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 22:02 UTC | INTERPACE BIOSCIENCES, INC. IDXG · Entity 7296 | GrantStock option (right to buy) · Derivative | 43,750 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001493152-20-022840 · ownership.xml · derivative · entry 1 STOVER JACK E · CIK 0001203603 · Former officer and director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,750 Underlying: Common Stock · 43,750 shares Expires 2030-11-30 F1 · derivative.exercise_date: The options vest immediately. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 21:36 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Appreciation Right · Derivative | 125,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001179110-20-008207 · edgar.xml · derivative · entry 1 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-07-09 F1 · derivative.exercise_date: These stock appreciation rights vest 100% on the first anniversary of the grant date. Read SEC document |
| March 12, 2020 Filed Apr 6, 2020 21:46 UTC | INTERPACE BIOSCIENCES, INC. IDXG · Entity 7296 | GrantCommon Stock | 7,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-005921 · ownership.xml · nonDerivative · entry 1 STOVER JACK E · CIK 0001203603 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,271 Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 21:34 UTC | INTERPACE BIOSCIENCES, INC. IDXG · Entity 7296 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $8.18 | $0.00 |
DisclosureSEC source: 0001192482-20-000059 · edgar.xml · derivative · entry 2 STOVER JACK E · CIK 0001203603 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-01-22 F1 · derivative.exercise_date: The stock option is eligible to vest and become exercisable in equal installments on each of the first three anniversaries of the date of grant, subject to the reporting person's continued service with the Issuer through the applicable vesting dates. Read SEC document |
| July 26, 2019 Filed Jul 29, 2019 21:21 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 5,833 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0001179110-19-008865 · edgar.xml · derivative · entry 1 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,833 Underlying: Common Stock · 5,833 shares Expires 2029-07-26 F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:59 UTC | INTERPACE BIOSCIENCES, INC. IDXG · Entity 7296 | GrantStock Option (right to buy) · Derivative | 347,688 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001192482-19-000148 · edgar.xml · derivative · entry 2 STOVER JACK E · CIK 0001203603 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,688 Underlying: Common Stock · 347,688 shares Expires 2029-03-13 F3 · derivative.exercise_date: The stock options vest and become exercisable over a three-year period, in equal installments, commencing on March 13, 2020, subject to the reporting person's continued service with the Issuer. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:59 UTC | INTERPACE BIOSCIENCES, INC. IDXG · Entity 7296 | GrantCommon Stock | 86,922 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000148 · edgar.xml · nonDerivative · entry 1 STOVER JACK E · CIK 0001203603 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,300 F1 · shares: The restricted stock units vest annually, in equal installments, over a three-year period, commencing on March 13, 2020. F2 · price: Each restricted stock unit represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 05, 2018 Filed Dec 6, 2018 22:06 UTC | INTERPACE BIOSCIENCES, INC. IDXG · Entity 7296 | GrantStock Option (right to buy) · Derivative | 375,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001192482-18-000490 · edgar.xml · derivative · entry 2 STOVER JACK E · CIK 0001203603 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2028-12-05 F3 · derivative.exercise_date: The option award vests and becomes exercisable over a three-year period, in equal installments, commencing on December 5, 2019, subject to the reporting person's continued service with the Issuer. Read SEC document |
| December 05, 2018 Filed Dec 6, 2018 22:06 UTC | INTERPACE BIOSCIENCES, INC. IDXG · Entity 7296 | GrantCommon Stock | 60,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-18-000490 · edgar.xml · nonDerivative · entry 1 STOVER JACK E · CIK 0001203603 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,378 F1 · shares: The restricted units vest annually, in equal installments, over a three-year period, commencing on December 6, 2019. F2 · price: Each restricted unit represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 05, 2018 Filed Mar 8, 2019 21:18 UTC Amendment | INTERPACE BIOSCIENCES, INC. IDXG · Entity 7296 | GrantStock Option (right to buy) · Derivative | 348,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001192482-19-000124 · edgar.xml · derivative · entry 2 STOVER JACK E · CIK 0001203603 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,000 Underlying: Common Stock · 348,000 shares Expires 2028-12-05 F3 · shares: On December 6, 2018, the award of stock options was inadvertently overstated on the reporting person's Form 4 filing as 375,000 stock options. 348,000 stock options were awarded. F4 · derivative.exercise_date: The stock options vest and become exercisable over a three-year period, in equal installments, commencing on December 5, 2019, subject to the reporting person's continued service with the Issuer. Read SEC document |
| December 05, 2018 Filed Mar 8, 2019 21:18 UTC Amendment | INTERPACE BIOSCIENCES, INC. IDXG · Entity 7296 | GrantCommon Stock | 87,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000124 · edgar.xml · nonDerivative · entry 1 STOVER JACK E · CIK 0001203603 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,378 F1 · shares: On December 6, 2018, the award of restricted stock units was inadvertently omitted from the reporting person's Form 4 filing. The restricted stock units vest annually, in equal installments, over a three-year period, commencing on December 5, 2019. F2 · price: Each restricted stock unit represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 21:31 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 87,500 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001179110-18-010014 · edgar.xml · derivative · entry 1 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2028-07-26 F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date. Read SEC document |
| April 27, 2018 Filed May 1, 2018 22:30 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseWarrant (right to purchase) · Derivative | 47,100 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001179110-18-006015 · edgar.xml · derivative · entry 2 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,100 Underlying: Series B Convertible Preferred Stock · 1,177.5 shares Expires not disclosed F1 · price: The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-224315). F2 · derivative.expiration_date: The warrants are exercisable immediately at an exercise price of $0.425 per 0.025 share of Series B Convertible Preferred Stock and will expire on the 18-month anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware. Read SEC document |
| April 27, 2018 Filed May 1, 2018 22:30 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseCommon Stock | 47,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-006015 · edgar.xml · nonDerivative · entry 1 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,110 F1 · price: The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-224315). Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 22:32 UTC | INTERPACE BIOSCIENCES, INC. IDXG · Entity 7296 | GrantStock Option (right to buy) · Derivative | 224,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001493152-18-003194 · form4.xml · derivative · entry 2 STOVER JACK E · CIK 0001203603 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,000 Underlying: Common Stock · 224,000 shares Expires 2028-03-07 F4 · derivative.exercise_date: The option award vests and becomes exercisable over a three-year period, in equal installments, commencing on March 7, 2019, subject to the reporting person's continued service with the Issuer. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 22:32 UTC | INTERPACE BIOSCIENCES, INC. IDXG · Entity 7296 | GrantCommon Stock | 56,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-18-003194 · form4.xml · nonDerivative · entry 1 STOVER JACK E · CIK 0001203603 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,738 F1 · shares: The restricted units vest annually, in equal installments, over a three-year period, commencing on March 7, 2019. F2 · price: Each restricted unit represents the contingent right to receive one share of common stock of Interpace Diagnostics Group, Inc. (the "Issuer"). F3 · balance_after: Reflects 1-for-10 reverse stock split, effective as of December 28, 2016. Read SEC document |
| September 26, 2017 Filed Sep 27, 2017 21:11 UTC | INTERPACE BIOSCIENCES, INC. IDXG · Entity 7296 | GrantStock Option (right to buy) · Derivative | 345,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001493152-17-010979 · form4.xml · derivative · entry 1 STOVER JACK E · CIK 0001203603 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,000 Underlying: Common Stock · 345,000 shares Expires 2018-09-26 F1 · derivative.exercise_date: The stock option award vests and becomes exercisable over a period of one year in twelve equal installments, commencing on the 15th day of each calendar month, subject to the reporting person's continued service with the issuer. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 21:00 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 1,500 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001179110-17-008993 · edgar.xml · derivative · entry 1 STOVER JACK E · CIK 0001203603 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2027-06-12 F1 · derivative.exercise_date: These options vest over one year from the grant date in 12 equal monthly installments. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 20:09 UTC | INTERPACE BIOSCIENCES, INC. IDXG · Entity 7296 | GrantStock Option (right to buy) · Derivative | 134,602 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001192482-17-000080 · edgar.xml · derivative · entry 2 STOVER JACK E · CIK 0001203603 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,602 Underlying: Common Stock · 134,602 shares Expires 2027-03-16 F1 · derivative.exercise_date: The option award vests and becomes exercisable over a one-year period, commencing on March 16, 2017, in twelve equal installments, on the 15th day of each calendar month, subject to the reporting person's continued service with the issuer. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 20:25 UTC | INTERPACE BIOSCIENCES, INC. IDXG · Entity 7296 | GrantStock Option (right to buy) · Derivative | 326,368 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0001192482-16-000733 · edgar.xml · derivative · entry 2 STOVER JACK E · CIK 0001203603 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,368 Underlying: Common Stock · 326,368 shares Expires 2026-10-14 F1 · derivative.exercise_date: The options will vest in equal monthly installments over a period of one year. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.